Problemi correnti
La malattia pneumococcica tra vecchi e nuovi vaccini
PNEUMOCOCCAL DISEASE BETWEEN OLD AND NEW VACCINES
Rosario Cavallo
Pediatra di famiglia, Salice Salentino (Lecce)
Dicembre 2010 - pagg. 636 -643
Abstract
New pneumococcal conjugate vaccines (PVCs) that have a wider coverage range and that
will probably replace PCV7 in universal immunization programmes have been recently
authorized. The social burden ascribable to pneumococcal disease in Italy is controversial
and the utilization of PCV7 seems not to have contributed to its reduction as it was hoped;
at the same time a displacement of the strains responsible for pneumococcal disease has
been observed with a reduction in vaccine strains and an increase in non-vaccine strains
that before were less frequent. At present there is the opportunity to assess the epidemiology
of the pnemococcal disease and its variation after vaccination.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. American Academy of Pediatrics. Rapporto
del Comitato sulle malattie infettive. Red Book
ed. 2009 - Capitolo Pneumococco: 524-35.
2. Siegrist CA. Vaccine Immunology. General
Aspect of Vaccination: 17-37.
3. Weekly epidemiological record 23 March
2007, 82nd Year / No. 12, 2007, 82, 93-104;
http://www.who.int/wer
4. Delibera AIFA del 16-04-2010. GU n° 100
del 30-04-2010.
5. www.iss.it rapporti Istisan 09/29 Studio
ICONA 2008.
6. Vaccinare oggi & domani, anno 2010-vol.1
Suppl.al fascicolo 1, Introduzione degli Autori.
7. Wardlaw TM, Johansson EW, Hodge M.
Pneumonia, the forgotten killer of the children;
http://www.who.int/child_adolescent_
health/documents/9280640489/fr/index.html.
8. Protocollo per la Sorveglianza delle malattie
infettive da Streptococcus pneumoniae in
Piemonte e Puglia; http://epidem.aslal.it/uploads/
documenti/17_protocollo_pnc.PDF.
9. Piano Nazionale Vaccini 2005-2007; GU,
Suppl ordinario 14 aprile 2005, pag. 33.
10. Castiglia P, Gallisai D, Sotgiu G. Epidemiology
of invasive pneumococcal infections in
Sardinian children; Poster of ISPPD-4 Helsinki
2004 (4° Simposio Internazionale sulle patologie
da Pneumococco).
11. Romano G, Poli A, Tardivo S. Invasive
pneumococcal diseases in age group 0-36
months: results from a perspective surveillance
program in Northern-eastern Italy.
Poster of ISPPD-4, Helsinki 2004.
12. D’Ancona F, Salmaso S, Barale A, et al.,
and Italian PNC-Euro Working Group. Incidence
of vaccine preventable pn. Invasive infections
and blood colture practices in Italy.
Vaccine 2005;23:2494-500.
13. http://www.simi.iss.it/dati.htm.
14. Azzari C, Moriondo M, Indolfi G, et al.
Molecular detection methods and serotyping
performed directly on clinical samples improve
diagnostic sensitivity and reveal increased
incidence of invasive disease by Streptococcus
pneumoniae in Italian children. J Med
Microbiol 2008;57:1205-12.
15. Lepoutre A, Varon E, Georges S, Gutmann
L, Lévy-Bruhl D. Impact of infant pneumococcal
vaccination on invasive pneumococcal diseases
in France, 2001-2006. Euro Surveill
2008;13(35).pii:18962.
16. Haut Conseil de la Santé Publique AVIS relatif
à la vaccination par le vaccin pneumococcique
conjugué 13-valent, 11 décembre 2009;
www.hcsp.fr.
17. Hsu HE, Shutt KA, Moore MR, et al. Effect
of Pneumococcal Conjugate Vaccine on
Pneumococcal Meningitis. N Engl J Med
2009;360:244-56.
18. Kaye P, Malkani R, Martin S, e al. IPD in
England & Wales after PCV7; potential impact
of 10 and 13-valent vaccines; http://www.
hpa.nhs.uk/Topics/InfectiousDiseases/Infect
ionsAZ/Pneumococcal/.
19. Rodenburg GD, de Greeff SC, Jansen AG,
et al. Effects of pneumococcal conjugate vaccine
2 years after its introduction, the Netherlands
Emerging Infectious Diseases; www.
cdc.gov/eid. Vol. 16, No. 5, May 2010.
20. Rozenbaum MH, Sanders EAM, van Hoek
AJ, et al. Cost effectiveness of pneumococcal
vaccination among Dutch infants: economic
analysis of the seven valent pneumococcal conjugated
vaccine and forecast for the 10 valent
and 13 valent vaccines. BMJ 2010;340: c2509.
21. Almagro CM, Jordan I, Gene A, Latorre C,
Garcia-Garcia JJ, Pallares R. Emergence of invasive
pneumococcal disease caused by nonvaccine
serotypes in the era of 7-valent conjugate
vaccine. Clin Infect Dis 2008;46:174-82.
22. Piano Nazionale Vaccini 2005-2007. GU,
Suppl. ordinario 14 aprile 2005, pag. 36.
23. http://www.epicentro.iss.it/temi/infettive/
pdf/tabelle-sito-simi2.pdf.
24. Durando P. Crovari P, Ansaldi F, et al. Universal
childhood immunisation against Streptococcus
pneumoniae: The five-year experience
of Liguria Region, Italy. Vaccine 2009;
27:3459-62.
25. http://www.sanita.regione.lombardia.it/
cs/Satellite?c=Redazionale_P&childpagenam
e=DG_Sanita/Detail&cid=1213323009201&pa
ckedargs=menu-to-render%3D1213277-
441847&pagename=DG_SANWrapper&rendermode=
previewnoinsite.
26. http://www.epicentro.iss.it/regioni/emilia/
pdf/malattieInvBattER09.pdf.
27. Pavia M, Bianco A, Nobile CGA, Marinelli,
P, Angelillo IF. Efficacy of pneumococcal vaccination
in children younger than 24 months: a meta-analysis. Pediatrics 2009;123;e1103-
e1110.
28. Nelson JC, J.ackson M, Yu O, et al. Impact
of the introduction of pneumococcal conjugate
vaccine on rates of community acquired pneumonia
in children and adults Vaccine 2008;26:
4947-54.
29. Byington CL, Korgenski K, Daly J, Ampofo
K, Pavia A, Mason EO. Impact of the pneumococcal
conjugate vaccine on pneumococcal
parapneumonic empyema. Pediatr Infect Dis J
2006;25:250-4.
30. Ministero della Salute. Circolare 0024720-
P del 27-05-2010.
31. Piano Nazionale Vaccini 2005-2007. GU
Suppl. ordinario 14 aprile 2005, pag. 30-31.
32. www.ministerodellasalute.it/malattieinfettiveevaccinazioni/
coperture.
33. Piano Nazionale Vaccini 1998-2000 PAG
17; http://docs.google.com/viewer?a=v&q=
cache:1Hj7rDSOb4J:www.salute.gov.it/imgs/
C_17_pubblicazioni_77_allegato.pdf+PIANO+
NAZIONALE+VACCINI+2000&hl=it&gl=it&p
id=bl&srcid=ADGEESgOQdbiziLioQ3SOkOz
u_MjMWbFlTfV7IJ6NsHh0_l0NgunwivGdVr
wFLrXtx8U5F4XjGauhztToA6GjlLjp3-
UlQWHEWpCaKDsOG8p3S1ROyRtJarSRpEk9lad7uKrj9zv0jU5&
sig=AHIEtbS3F2NOxJ
w1F66i56xv-8khd4C73w
34. Piano Nazionale per l’eliminazione di morbillo
e rosolia congenital. GU Suppl. ordinario
n° 195 al n° 297 del 23-12-2003; http://www.
governo.it/backoffice/allegati/20894-1712.
pdf.
35. http://www.epicentro.iss.it/focus/morbillo/
morbillo.asp.
36. Giambi C, Filia A, Ciofi degli Atti ML, Rota
MC, Salmaso S. Allarme rosolia: promuovere
gli interventi per vaccinare le donne
suscettibili in età fertile. B. e. n. Vol. 21 numero
5 maggio 2008; http://www.epicentro.
iss.it/ben/2008/maggio/1.asp.
37. Gruppo ACP Salento e ACP Puglia-Basilicata.
Prevalenza di mamme sieronegative per
rosolia in Puglia. Quaderni acp, in pubblicazione.
38. Piano Nazionale Vaccini 2005-2007, pag.
16-17.
39. Marchetti M, Colombo GL. Cost-effectiveness
of universal pneumococcal vaccination
for infants in Italy. Vaccine 2005;23(37):4565-
76.
40. Melegaro A, Edmunds WJ. Cost-effectiveness
analysis of pneumococcal coniugate vaccination
in England and Wales. Vaccine 2004;
22:4203-14.
41. Grandori L, Bonati M, Gangemi M. 8 passi
di prevenzione a tutela della salute dei bambini.
Medico e Bambino 2006;25:643-6.
Corrispondenza: rcavallo58@gmail.com